PEN Penumbra, Inc. Loading...

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
12:00
Jul 29 ◎
Mike Mahoney Chairman and Chief Executive Officer, Boston Scientific Cor… BSX Q2 FY26 call
The acquisition of Penumbra is expected to close in H2 2026, adding to BSX's cardiovascular product portfolio and strengthening long-term growth.
PEN
HIGH
12:00
Apr 22 ◎
Mike Mahoney Chairman and Chief Executive Officer, Boston Scientific Cor… BSX Q1 FY26 call
The acquisition is on track to close, bringing a differentiated portfolio and a strong team to BSX.
PEN
HIGH
13:00
Feb 04 ◎
Mike Mahoney CEO, Boston Scientific Corporation BSX Q4 FY25 call
Acquisition of Penumbra is expected to close in 2026, adding mechanical thrombectomy and neurovascular capabilities.
PEN
HIGH
21:30
Jan 29 ◎
Jason Beach SYK Q4 FY25 call
Stryker acknowledged its ischemic neurovascular business has been pressured for two years, with a new large-bore aspiration catheter only in early US launch, while hemorrhagic has overtaken market leadership — a mixed competitive signal for neurovascular rivals. — Competitors in ischemic stroke aspiration still have a window before Stryker's Broadway launch scales globally, while Stryker's hemorrhagic strength raises the bar in that segment.
PEN
MED

About PEN Analyst Coverage

Buzzberg tracks PEN (Penumbra, Inc.) across 1 sources. 0 bullish vs 0 bearish calls from 2 analysts. Sentiment: evenly split. 4 total trade ideas tracked. Latest voices: Mike Mahoney, Jason Beach.